BioSpace News Archive

Helius Medical Technologies, Inc., a neurotech company focused on neurological wellness, announced it received market authorization from the Australian Therapeutic Goods Administration for the sale of PoNS as a Class IIa medical device.

ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, reported its financial and operating results for the third quarter ended September 30, 2021, and provided a business update.

Jounce Therapeutics, Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.

Passage Bio, Inc., a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, reported financial results for the third quarter ended September 30, 2021 and provided recent business highlights.

Antares Pharma, Inc., a specialty pharmaceutical company, reported financial and operating results for the third quarter ended September 30, 2021 with record revenue of $48.2 million and net income of $5.4 million, or $0.03 per basic and diluted earnings per share.

Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer, announced that Charles Lin, Ph.D., Senior Vice President, Biology, will participate in the Emerging Trends and Therapeutics in Oncology panel at the BMO Biopharma Spotlight Series on Monday, November 8 at 3:25 p.m. Eastern Time.

Baudax Bio, Inc., a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, reported financial results for the three and nine months ended September 30, 2021, and provided key metrics around the ongoing commercial rollout of ANJESO® injection and updated status of neuromuscular blocking agent BX1000 dose escalation study.

Chimerix, a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, reported positive topline data from its 50-patient efficacy analysis of ONC201 for the treatment of recurrent H3 K27M-mutant glioma.

Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems, announced that members of its senior management team are scheduled to participate in four upcoming investor conferences.

Shattuck Labs, Inc. announced it will host a live webcast presentation highlighting the clinical data being presented at the 2021 Society for Immunotherapy of Cancer on Friday, November 12, 2021 at 8:00 a.m. ET.